Lindbrook Capital’s Relmada Therapeutics RLMD Stock Holding History

Lindbrook Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,500	Closed	-$8.1K	–	2890
2024 Q3	$8.1K	Hold	2,500	–	–	﹤0.01%	1792
2024 Q2	$7.5K	Hold	2,500	–	–	﹤0.01%	1790
2024 Q1	$11.6K	Hold	2,500	–	–	﹤0.01%	1489
2023 Q4	$10.3K	Hold	2,500	–	–	﹤0.01%	1532
2023 Q3	$7.5K	Hold	2,500	–	–	﹤0.01%	1556
2023 Q2	$6.15K	Hold	2,500	–	–	﹤0.01%	1703
2023 Q1	$5.65K	Hold	2,500	–	–	﹤0.01%	1801
2022 Q4	$8.72K	Sell	2,500 -96	-4%	-$843	﹤0.01%	1504
2022 Q3	$96K	Buy	2,596 +73	+3%	+$2.02K	0.02%	444
2022 Q2	$48K	Buy	2,523 +23	+0.9%	+$502	0.01%	671
2022 Q1	$67K	Hold	2,500	–	–	0.01%	592
2021 Q4	$56K	Buy	+2,500	New	+$55.6K	0.01%	678

Other funds holding RLMD

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lindbrook Capital's RLMD Position: Q4 2024 in Review

Lindbrook Capital sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 2,500 shares — an estimated $8.1K sold.

Lindbrook Capital first reported a position in RLMD in Q4 2021 and held it in 12 quarters. The position peaked at $96K in Q3 2022. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

Lindbrook Capital reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
Lindbrook Capital sold 2,500 Relmada Therapeutics shares in Q4 2024, an estimated $8.1K.
Lindbrook Capital first reported a position in Relmada Therapeutics in Q4 2021 and held it in 12 quarters.
Lindbrook Capital's Relmada Therapeutics position peaked at $96K in Q3 2022.
48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.